This mutation occurs in about 30% of human breast cancers, where it leads to gain-of-function mutations in gene PIK3CA that activate the PI3K-AKT-signaling pathway constantly, thereby uncoupling the EGFR response from AKT signaling [16]. This evidence concerns the gene PIK3CA and breast carcinoma.